Hormonal Treatment Articles & Analysis: Older
6 news found
Elacestrant demonstrated longer progression-free survival (PFS) vs SOC endocrine therapy with medians up to 8.6 months, positively associated with the duration of prior treatment with CDK4/6 inhibitors Elacestrant side effects were manageable and consistent with previously reported results Results demonstrate that elacestrant may have the potential to become a new standard of care as a ...
Study plans to investigate elinzanetant as non-hormonal treatment for vasomotor symptoms caused by endocrine therapy in breast cancer patients Elinzanetant is an innovative non-hormonal development compound in development for the treatment of vasomotor symptoms during menopause Bayer, a global leader in women’s ...
ByBayer AG
The latest research builds on the 2019 FAKTION trial based on the use of capivasertib, an investigational breast cancer drug developed by AstraZeneca that blocks the activity of a protein called AKT that has been shown to contribute to resistance to hormone therapy. The 2019 research found that, by combining capivasertib with a standard hormonal ...
Upon relapse when the disease will metastasize or spread, androgen deprivation therapy (ADT) is the cornerstone of treatment for this hormone-sensitive disease. Approximately 5% of men will already suffer from prostate cancer with distant metastases when first diagnosed. Men with metastatic hormone-sensitive prostate cancer (mHSPC) will start ...
ByBayer AG
It is encoded by the gene ESR1, which is known to be frequently mutated in metastatic breast cancers in patients who previously received hormonal treatment for primary breast cancer. Therefore, ESR1 mutation has been considered an acquired resistance mechanism to hormonal therapy. ...
Postmenopausal women with Recurrence Score results 0-25 were not observed to show benefit from chemotherapy and may avoid the associated side effects of the treatment. Importantly, no chemotherapy benefit was observed regardless of the number of affected nodes, tumour grade, or size. ...